Annals of Neurology · 2021 · 38 citations · 15 references
MedicineInfectious DiseasesNeurologyMedical MicrobiologyNeuroimmunologyNeuroinfectious DiseasesCentral Nervous System InfectionsCerebrospinal Fluid BiomarkersNeuropathology Of InfectionCerebrospinal Fluid DiagnosticsSars-cov-2 Infection
This study was undertaken to assess whether SARS-CoV-2 causes a persistent central nervous system infection. SARS-CoV-2-specific antibody index and SARS-CoV-2 RNA were studied in cerebrospinal fluid following COVID-19. Cerebrospinal fluid was assessed between days 1 and 30 (n = 12), between days 31 and 90 (n = 8), or later than 90 days (post-COVID-19, n = 20) after COVID-19 diagnosis. SARS-CoV-2 RNA was absent in all patients, and in none of the 20 patients with post-COVID-19 syndrome were intrathecally produced anti-SARS-CoV-2 antibodies detected. The absence of evidence of SARS-CoV-2 in cerebrospinal fluid argues against a persistent central nervous system infection as a cause of neurological or neuropsychiatric post-COVID-19 syndrome. ANN NEUROL 2022;91:150-157.
15
Evolution of antibody immunity to SARS-CoV-2
Christian Gaebler, Zijun Wang, Julio C. C. Lorenzi et al. · Nature · 2021 · 1.8K citations · Full text
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series
Jakob Matschke, Marc Lütgehetmann, Christian Hagel et al. · The Lancet Neurology · 2020 · 1.4K citations · Full text